Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — November 2019

Planlagt Fastgjort Låst Flyttet Genmab
1.6k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • G Offline
    G Offline
    GeorgeBest
    wrote on sidst redigeret af
    #358

    PM fra Genmab https://ir.genmab.com/news-releases/news-release-details/genmab-announces-data-be-presented-2019-ash-annual-meeting

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #359

      thks, that makes life easier

      1 Reply Last reply
      0
      • BulderB Offline
        BulderB Offline
        Bulder
        wrote on sidst redigeret af
        #360

        h
        ex-cd38 https://ash.confex.com/ash/2019/webprogram/Paper125788.html

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #361

          Mim8 utilized the Duobody® platform / Novo Nordisk / hemophilia A https://ash.confex.com/ash/2019/webprogram/Paper122817.html

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #362

            Flot indtil videre. Gen3013 oral, og endvidere 6 orale dara præsentationer. Og chance for Andromeda som LB.

            1 Reply Last reply
            0
            • BulderB Offline
              BulderB Offline
              Bulder
              wrote on sidst redigeret af
              #363

              7 orale

              1 Reply Last reply
              0
              • SolsenS Offline
                SolsenS Offline
                Solsen
                wrote on sidst redigeret af
                #364

                Fandme flot !

                1 Reply Last reply
                0
                • SolsenS Offline
                  SolsenS Offline
                  Solsen
                  wrote on sidst redigeret af
                  #365

                  Så slipper konen for at tale med mig i aften 😉

                  1 Reply Last reply
                  0
                  • P Offline
                    P Offline
                    Peter_Panik
                    wrote on sidst redigeret af
                    #366

                    @ The Note 10.30. Jeg har længe og er stadig yderst positiv på Genmab, og der kommer jo den ene gode historie efter den anden. Vi kan jo og har tidligere set, at andre "store" spillere har en trading interesse i aktien både på den korte og mellemlange bane, og det kan give udsving, som river de nervøse midt over.

                    1 Reply Last reply
                    0
                    • BulderB Offline
                      BulderB Offline
                      Bulder
                      wrote on sidst redigeret af
                      #367

                      Vigtigt gen3013: All CRS events were non-severe and did not lead to discontinuation.

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #368

                        i think that is the most important line I take away from it for now; safety was Jan's biggest concern, wasn't it. Seems ok so far.

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          gentogen
                          wrote on sidst redigeret af
                          #369

                          Lidt Ofa: HCVAD-O is a safe and highly effective regimen in pts with CD20+ Ph-negative B-ALL. This regimen achieves excellent outcomes in the AYA population (...) All but 1 pt (98%) achieved CR (2 after 2 cycles)...Using historical control pts, there was a trend towards improved OS with HCVAD-O versus HCVAD-R

                          1 Reply Last reply
                          0
                          • SolsenS Offline
                            SolsenS Offline
                            Solsen
                            wrote on sidst redigeret af
                            #370

                            hexacd38 ser også spændende ud specielt i new diagnosed

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              gentogen
                              wrote on sidst redigeret af
                              #371

                              The preliminary analysis of the GELLC7 trial showed that the addition of consolidation with ofatumumab after 12 cycles of prior treatment with ibrutinib was well tolerated and elicited a deeper response.(...)In 20 patients receiving the consolidation with ofatumumab an improvement in response was observed, with 8/20 patients (40%) attaining a CR (7 patients converted PR to CR, and one patient SD to CR

                              1 Reply Last reply
                              0
                              • BulderB Offline
                                BulderB Offline
                                Bulder
                                wrote on sidst redigeret af
                                #372

                                Hex-cd38 er stærkere end dara til CDC. Og på niveau med dara til ADCC og ADCP.

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #373

                                  and they are not afraid to say it. Hope they can get this into the clinic fast

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #374

                                    862 Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study https://ash.confex.com/ash/2019/webprogram/Paper126378.html

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #375

                                      695 Efficacy and Tolerability of (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study https://ash.confex.com/ash/2019/webprogram/Paper121694.html

                                      1 Reply Last reply
                                      0
                                      • BulderB Offline
                                        BulderB Offline
                                        Bulder
                                        wrote on sidst redigeret af
                                        #376

                                        862: Nice, 83% MRD-neg!

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #377

                                          from
                                          Luciano J Costa
                                          @End_myeloma
                                          https://ash.confex.com/ash/2019/webprogram/Paper123401.html
                                          This is big news. I honestly can't think of any other intervention in MM with this much impact in survival. Congratulations to the Alcyone team
                                          @mvmateos
                                          #ASH2019 #mmsm

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger